Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production
(2012) In PLoS ONE 7(2).- Abstract
Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-associated mortality that can occur with any type of transfusion and is thought to be primarily due to donor antibodies activating pulmonary neutrophils in recipients. Recently, a large prospective case controlled clinical study of cardiac surgery patients demonstrated that despite implementation of male donors, a high incidence of TRALI still occurred and suggested a need for additional interventions in susceptible patient populations. To examine if intravenous immunoglobulin (IVIg) may be effective, a murine model of antibody-mediated acute lung injury that approximates human TRALI was examined. When BALB/c mice were injected with the anti-major... (More)
Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-associated mortality that can occur with any type of transfusion and is thought to be primarily due to donor antibodies activating pulmonary neutrophils in recipients. Recently, a large prospective case controlled clinical study of cardiac surgery patients demonstrated that despite implementation of male donors, a high incidence of TRALI still occurred and suggested a need for additional interventions in susceptible patient populations. To examine if intravenous immunoglobulin (IVIg) may be effective, a murine model of antibody-mediated acute lung injury that approximates human TRALI was examined. When BALB/c mice were injected with the anti-major histocompatibility complex class I antibody 34-1-2s, mild shock (reduced rectal temperature) and respiratory distress (dyspnea) were observed and pre-treatment of the mice with 2 g/kg IVIg completely prevented these symptoms. To determine IVIg's usefulness to affect severe lung damage, SCID mice, previously shown to be hypersensitive to 34-1-2s were used. SCID mice treated with 34-1-2s underwent severe shock, lung damage (increased wet/dry ratios) and 40% mortality within 2 hours. Treatment with 2 g/kg IVIg 18 hours before 34-1-2s administration completely protected the mice from all adverse events. Treatment with IVIg after symptoms began also reduced lung damage and mortality. While the prophylactic IVIg administration did not affect 34-1-2s-induced pulmonary neutrophil accumulation, bone marrow-derived neutrophils from the IVIg-treated mice displayed no spontaneous ROS production nor could they be stimulated in vitro with fMLP or 34-1-2s. These results suggest that IVIg prevents murine antibody-mediated acute lung injury at the level of neutrophil ROS production and thus, alleviating tissue damage.
(Less)
- author
- Semple, John W LU ; Kim, Michael ; Hou, Jing ; McVey, Mark ; Lee, Young Jin ; Tabuchi, Arata ; Kuebler, Wolfgang M ; Chai, Zhong-Wei and Lazarus, Alan H
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- keywords
- Acids, Acute Lung Injury, Animals, Blood Transfusion, Chemokine CXCL2, Edema, Humans, Hypothermia, Immunoglobulins, Intravenous, Lung, Male, Mice, Mice, Inbred BALB C, Mice, SCID, Neutrophils, Reactive Oxygen Species, Survival Analysis, Journal Article, Research Support, Non-U.S. Gov't
- in
- PLoS ONE
- volume
- 7
- issue
- 2
- article number
- e31357
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- scopus:84857186465
- pmid:22363629
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0031357
- language
- English
- LU publication?
- no
- id
- 271e7b08-da9c-4ca4-bf01-43101bd1b046
- date added to LUP
- 2016-09-23 12:04:09
- date last changed
- 2024-04-19 09:18:52
@article{271e7b08-da9c-4ca4-bf01-43101bd1b046,
abstract = {{<p>Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-associated mortality that can occur with any type of transfusion and is thought to be primarily due to donor antibodies activating pulmonary neutrophils in recipients. Recently, a large prospective case controlled clinical study of cardiac surgery patients demonstrated that despite implementation of male donors, a high incidence of TRALI still occurred and suggested a need for additional interventions in susceptible patient populations. To examine if intravenous immunoglobulin (IVIg) may be effective, a murine model of antibody-mediated acute lung injury that approximates human TRALI was examined. When BALB/c mice were injected with the anti-major histocompatibility complex class I antibody 34-1-2s, mild shock (reduced rectal temperature) and respiratory distress (dyspnea) were observed and pre-treatment of the mice with 2 g/kg IVIg completely prevented these symptoms. To determine IVIg's usefulness to affect severe lung damage, SCID mice, previously shown to be hypersensitive to 34-1-2s were used. SCID mice treated with 34-1-2s underwent severe shock, lung damage (increased wet/dry ratios) and 40% mortality within 2 hours. Treatment with 2 g/kg IVIg 18 hours before 34-1-2s administration completely protected the mice from all adverse events. Treatment with IVIg after symptoms began also reduced lung damage and mortality. While the prophylactic IVIg administration did not affect 34-1-2s-induced pulmonary neutrophil accumulation, bone marrow-derived neutrophils from the IVIg-treated mice displayed no spontaneous ROS production nor could they be stimulated in vitro with fMLP or 34-1-2s. These results suggest that IVIg prevents murine antibody-mediated acute lung injury at the level of neutrophil ROS production and thus, alleviating tissue damage.</p>}},
author = {{Semple, John W and Kim, Michael and Hou, Jing and McVey, Mark and Lee, Young Jin and Tabuchi, Arata and Kuebler, Wolfgang M and Chai, Zhong-Wei and Lazarus, Alan H}},
issn = {{1932-6203}},
keywords = {{Acids; Acute Lung Injury; Animals; Blood Transfusion; Chemokine CXCL2; Edema; Humans; Hypothermia; Immunoglobulins, Intravenous; Lung; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Neutrophils; Reactive Oxygen Species; Survival Analysis; Journal Article; Research Support, Non-U.S. Gov't}},
language = {{eng}},
number = {{2}},
publisher = {{Public Library of Science (PLoS)}},
series = {{PLoS ONE}},
title = {{Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production}},
url = {{http://dx.doi.org/10.1371/journal.pone.0031357}},
doi = {{10.1371/journal.pone.0031357}},
volume = {{7}},
year = {{2012}},
}